GR43828 - A Phase I, Multicenter, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Genentech, Inc.
Start Date
January 24, 2023
End Date
January 14, 2028
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Genentech, Inc.
Start Date
January 24, 2023
End Date
January 14, 2028